GEHC

GE Healthcare Technologies Inc. - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. GE Healthcare Technologies Inc. operates as a global provider of advanced medical technology, pharmaceutical diagnostics, and AI/cloud solutions. As of the reporting date, the company was organized into four reportable segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). A subsequent event announced on April 29, 2026, indicates a restructuring to combine Imaging and AVS into a new "Advanced Imaging Solutions" segment, effective for future reporting.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 7.4% year-over-year, driven by a 2.9% organic growth rate. Growth was led by the PDx segment (+21.7%), Imaging (+7.4%), and AVS (+8.2%), partially offset by a decline in PCS (-6.5%).
• Profitability Decline: Operating income decreased 18.2% to $515 million. This was primarily due to a $36 million decrease in gross profit and a $79 million increase in operating expenses. Gross margin compression was driven by cost inflation, incremental tariffs (impacting operating income by ~$90 million), and a supplier issue in the PDx segment.
• Net Income Impact: Net income attributable to GE HealthCare fell 31.0% to $389 million. A significant factor was the absence of a $97 million non-recurring gain from the remeasurement of the Nihon Medi-Physics (NMP) equity investment recorded in Q1 2025.
• Acquisition Activity: The company acquired Intelerad for approximately $2,297 million in cash during the quarter, funded by new borrowings and existing cash. This acquisition significantly impacted investing cash flows, which turned negative by $2,500 million.

Outlook, Risks, and Management Commentary

• Tariff Impact: Management highlighted that tariffs imposed in early 2025 and 2026 materially impacted operating income by approximately $90 million and cash flows by $110 million in Q1 2026. The company does not expect mitigation actions to fully offset these costs.
• Geopolitical Risks: Ongoing conflicts in Russia/Ukraine and the Middle East continue to pose risks to supply chains and logistics. The company reported $54 million in revenues from Russia and Ukraine in Q1 2026.
• China Market: Revenues in the China region decreased 4.4%, attributed to increased competition from local companies and volume-based procurement policies.
• Capital Allocation: The company repurchased 1.4 million shares for $100 million, leaving $700 million available under its current authorization. Dividends of $0.035 per share were declared.
• Legal Contingencies: A significant legal matter involving the U.S. Anti-Terrorism Act and contracts with the Iraqi Ministry of Health remains pending following a Court of Appeals decision in April 2026. Additionally, an ongoing IRS audit of GE consolidated returns (2016-2020) could result in material indemnification obligations.

Investor Verification Checklist

• Tariff Exposure: Verify the sustainability of the $90 million operating income impact from tariffs and the timeline for potential refunds announced by U.S. Customs.
• Intelerad Integration: Assess the preliminary purchase price allocation for the $2.3 billion Intelerad acquisition and the timeline for realizing projected synergies.
• PCS Segment Performance: Investigate the 6.5% revenue decline and 79.8% EBIT drop in the Patient Care Solutions segment to determine if this is a cyclical timing issue or a structural demand shift.
• Legal Liability: Monitor the status of the Iraqi Ministry of Health litigation and the potential financial exposure from the IRS audit of the pre-spin-off GE tax years.
• China Market Dynamics: Evaluate the long-term impact of volume-based procurement policies on the PDx and Imaging segments in China.